Ritlecitinib 50mg capsules

AbstractRitlecitinib and baricitinib are recently approved systemic treatments for severe alopecia areata (AA). Both demonstrated superiority over placebo in hair regrowth measured by the Severity of Alopecia Tool (SALT), but they have not been directly compared in randomized controlled trials (RCTs). We conducted a systematic review of RCTs evaluating treatments in AA and estimated the efficacy and safety of ritlecitinib and baricitinib at Week 24 using Bayesian network meta‐analysis. To adjust and explore effect modifiers, population‐adjusted indirect comparison was performed via multilevel network meta‐regression (ML‐NMR) using ritlecitinib individual patient data (IPD). Co‐primary endpoints were SALT ≤20 and SALT ≤10 at Week 24. Unanchored population adjusted ITCs were also computed to evaluate SALT ≤10 and SALT ≤20 endpoints at Week 48/52. Four RCTs (ALLEGRO 2a [NCT02974868], ALLEGRO 2b/3 [NCT03732807], BRAVE‐AA1 [NCT03570749] and BRAVE‐AA2 [NCT03899259]) were included. No evidence of a difference between ritlecitinib 50 mg and baricitinib 4 mg on SALT ≤10 (odds ratio, OR: 0.96, 95% credible interval, CrI: 0.18–7.21) and SALT ≤20 (OR: 2.16, 95% CrI: 0.48–16.46) at Week 24 was found. ML‐NMR using ALLEGRO IPD adjusted for sex, SALT score at baseline, duration of current episode and disease duration found evidence of effect modification, although relative efficacy between ritlecitinib 50 mg and baricitinib 4 mg remained unchanged. Unanchored population‐adjusted ITC at Week 48/52 was consistent with previous results. We found similar efficacy between ritlecitinib 50 mg and baricitinib 4 mg. These ITCs was informed by only four RCTs, uncertainty was considerable, and there was evidence of effect modification, highlighting the need for further quality research in AA.

Abstract licence: CC BY-NC 4.0

Background: Alopecia areata (AA) typically presents as round patches of hair loss (e.g., scalp, eyebrow/eyelash, and body), has an unpredictable disease course, and may relapse and remit. AA is a condition with a lifetime risk of approximately 2% in the global population with an annual incidence rate ranging from 2.53 to 26 per 100,000. This comprehensive systematic review and meta-analysis was performed to determine the safety and efficacy of Ritlecitinib in patients with AA. Methods: A systematic search was conducted in PubMed and Cochrane CENTRAL Library for randomized controlled trials (RCTs). We used mean difference with 95% confidence intervals to assess the effectiveness and odds ratio to assess the safety profile. A total of 65 publications were identified through a database search. Following two stages of screening, we included 13 publications. All the studies were parallel and double-blind RCTs and published between 2020 and 2022. Results: Our analysis revealed a significant reduction in SALT score at week 12 and week 24 of (−17.43 [−24.67 to −10.20]; p < 0.0001) and (−20.95 [−29.01 to −12.89]; p < 0.0001), respectively, in patients treated with Ritlecitinib compared to placebo. Furthermore, a significant improvement in PGIC score at week 24 was observed. Additionally, Ritlecitinib revealed a slightly higher reduction in AASIS score compared to placebo; however, this difference was statistically non-significant. Notably, the Ritlecitinib group experienced a higher frequency of headaches, acne and nasopharyngitis compared to placebo, while the placebo group reported a greater occurrence of serious adverse events compared to the Ritlecitinib group. This higher rate of serious events in the placebo arm could be explained by the placebo effect, although these differences were statistically non-significant. Conclusions: These findings suggest that Ritlecitinib holds promise as an effective treatment for AA with an acceptable safety profile, warranting further investigation in larger cohorts and long-term studies.

Abstract licence: CC BY 4.0

BackgroundScant evidence exists for the relative efficacy of therapies for alopecia areata (AA)-including those approved by the Food and Drug Administration, namely, baricitinib, deuruxolitinib, and ritlecitinib.AimsWe determined the relative efficacy and safety of monotherapy with janus kinase inhibitors (JAKIs), apremilast, and dupilumab.MethodsFollowing a systematic review, we conducted Bayesian network meta-analysis (NMAs) that produced Surface Under the Cumulative RAnking (SUCRA) values and point estimates for pairwise relative effects; we also performed sensitivity analyses.ResultsIn total, regimens with eight various JAKIs were compared, namely, ruxolitinib, ATI-501, baricitinib, brepocitinib, deuruxolitinib, ivarmacitinib, ritlecitinib, and tofacitinib. Our analyses ranked "deuruxolitinib 12 mg twice daily for 24 weeks," the most efficacious insofar as "proportion of participants achieving SALT ≤ 20 at 24 weeks" (SALT20) (SUCRA = 92.6%), and "proportion of participants achieving SALT ≤ 10 at 24 weeks" (SALT10) (SUCRA = 97.7%). As per SALT20, the highest-ranked regimen was more efficacious than "baricitinib 2 mg once daily for 24 weeks" (odds ratio [OR] = 5.37, 95% credible interval [CI] = 1.59, 13.70, p 20 (OR = 2.25, 95% CI = 1.56, 3.21, p ConclusionsWe produced high-quality evidence on the comparative effectiveness of monotherapies for AA with various regimens of 8 JAKIs, including the FDA-approved ones. Our findings can improve clinicians' decision-making and update guidelines for medical practice.

Abstract licence: CC BY

BACKGROUND Alopecia areata (AA) is an autoimmune illness with an underlying immuno-inflammatory etiology. It is characterized by nonscarring hair loss of the scalp, face, and/or body. Ritlecitinib is an orally administered drug that inhibits Janus Kinase 3 (JAK3) and the TEC kinase family, which are tyrosine kinases expressed in hepatocellular cancer and has been under investigation for the treatment of alopecia areata. OBJECTIVE Our meta-analysis is the first of its kind to synthesize the available literature on the topic, thereby studying the efficacy of Ritlecitinib in AA. METHODS A literature search was conducted on PubMed, Google Scholar, and Scopus to find relevant literature. RevMan 5.4 was used to perform statistical analysis. A random effects model was used to report the pooled Severity of Alopecia Tool (SALT) score. Risk Ratios along with their 95% Confidence Intervals (CIs), were reported for the outcomes. This review is registered with PROSPERO under the identifier: CRD42024539926. RESULTS A total of 4 studies were included in this systematic review and meta-analysis, including 411 patients. The mean age of patients in studies ranged from 14 to 43 years. The total number of patients who received Ritlecitinib was 205. All the included studies had a low risk of bias. Two trials, which reported responses of the reduction in SALT scores from baseline least square mean difference from placebo, were included in our review. The summary Mean Difference (MD) for the ritlecitinib versus placebo group was 30.58 (P < 0.00001). Other outcomes that were reported by our included studies were people who had <10 SALT scores and people who had <20 SALT scores. The pooled RR of patients who experienced adverse events was 1.27 (95% CI: 0.81 - 1.99, P = 0.30). CONCLUSIONS To sum up, ritlecitinib is a potentially effective treatment for Alopecia Areata that focuses on the complex pathophysiology of this somewhat debilitating illness. However, there still needs to be more research regarding ritlecitinib's full potential, which needs to be investigated with the aid of clinical and translational studies.

Abstract licence: CC BY

BackgroundVitiligo, a stigmatizing condition characterized by patchy depigmented skin, has an estimated global prevalence of 0.36%. This condition is a risk factor for anxiety, depression, and even suicidal ideation. Hitherto, no network meta-analysis has investigated the relative effect of vitiligo on relevant monotherapies.AimThe current study determined the relative effect of monotherapies for vitiligo through network meta-analyses (NMAs).MethodsThe peer-reviewed literature was systematically searched through PubMed and Scopus; studies that were eligible for quantitative analyses were those that were published in English and had an arm that investigated the effect of a monotherapy on vitiligo at 6 months. Studies of the randomized and observational designs were included.ResultsThe retrieved data were sufficient to analyze networks for phototherapy, Janus kinase inhibitors (JAKIs), calcineurin inhibitors, cyclosporine, corticosteroids, azathioprine, and minocycline. Modalities' effects, in each of the networks, were ranked with the surface under the cumulative ranking curve (SUCRA) metric; league tables were produced to depict agents' pairwise relative effects. Our secondary outcome was discontinuation due to any adverse event (AE) at 6 months.ConclusionsNo significant differences are observed among JAK inhibitors; however, upadacitinib, cyclosporine, ritlecitinib, and dexamethasone are significantly more effective than minocycline. Psoralen (oral) + ultraviolet A (PUVA) and narrow band ultraviolet B (NB-UVB) regimens show similar efficacy for repigmentation. Ruxolitinib 1.5% cream (once or twice daily), ruxolitinib 0.5% cream once daily, and ruxolitinib 0.15% cream once daily for 6 months do not differ significantly in efficacy. Mometasone furoate and tacrolimus 0.1% ointment are more effective than tacrolimus 0.03%.

Abstract licence: CC BY

Network and conventional meta-analyses can increase precision for clinical decision-making but risk producing misleading hierarchies when they pool ineffective, unsafe, or unapproved dosing regimens alongside licensed therapies. Using recent evidence syntheses in alopecia areata, we show how inclusion of small, underpowered dose strata and regimens that never advanced to pivotal trials or were not pursued for regulatory approval (for example, deuruxolitinib 4 mg twice‑daily {BID}, deuruxolitinib 12 mg BID, and ritlecitinib 200 mg loading doses) can distort pooled efficacy and safety estimates, elevate unapproved regimens in rankings, and invite inappropriate causal inferences. We outline key methodological safeguards and offer concrete recommendations as follows: prespecify exclusion or planned sensitivity analyses for unapproved doses, transparently report approval status and relevant regulatory actions (for example, clinical holds) alongside pooled safety estimates, avoid causal attributions from small strata and present uncertainty appropriately, and report sensitivity analyses that omit unapproved doses. Implementing these practices preserves the statistical advantages of meta-analysis while protecting clinicians, guideline panels, and payors from misleading inferences drawn from small or unrepresentative dose groups.

Abstract licence: CC BY